218 related articles for article (PubMed ID: 36408023)
21. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
22. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
[TBL] [Abstract][Full Text] [Related]
23. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.
Cheng R; Zhou Z; Liu Q
Cancer Med; 2023 Mar; 12(6):7389-7397. PubMed ID: 36373001
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Liu G; Kang S; Wang X; Shang F
Front Oncol; 2021; 11():669195. PubMed ID: 33987103
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Zhou K; Jiang C; Li Q
Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
[TBL] [Abstract][Full Text] [Related]
28. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
Zheng Z; Zhu G; Cao X; Cai H; Zhu H
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089
[TBL] [Abstract][Full Text] [Related]
29. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
Shao T; Zhao M; Liang L; Tang W
BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
Zheng Z; Lin J; Zhu H; Cai H
Front Public Health; 2022; 10():893387. PubMed ID: 35774581
[TBL] [Abstract][Full Text] [Related]
31. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
Wang H; Long Y; Xu Y; Liao L; Zhou Y
Front Public Health; 2023; 11():1137255. PubMed ID: 37033059
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C
BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.
Wang H; Liao L; Xu Y; Long Y; Wang Y; Zhou Y
Front Oncol; 2022; 12():1081750. PubMed ID: 36582798
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
Li F; Chen Y; Xiao D; Jiang S; Yang Y
Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
Zheng H; Xie L; Zhan M; Wen F; Xu T; Li Q
Clin Transl Oncol; 2018 Mar; 20(3):286-293. PubMed ID: 28785913
[TBL] [Abstract][Full Text] [Related]
40. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
